Additionally, Ganetespib enhances the sensitivity of mantle cell lymphoma (MCL) cells to the Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib, particularly in resistant cancer cells. This evidence concerns the gene BTK and cancer.